Navigation Links
NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

advantages over other pain therapies. NeurogesX' marketing authorization application to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application with the FDA in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

Neu
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015 GOJO, inventors of PURELL ... to antibiotic stewardship at the White House Forum.  GOJO ... health organizations and stakeholders at the White House Forum ... slow the emergence of antibiotic-resistant bacteria, detect resistant strains, ... the spread of resistant infections. "A primary ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... NEW YORK , June 1, 2015 /PRNewswire/ ... medical researcher  Eliseo Oreste Salinas , MD, MSc, ... and development. Dr. Salinas, who holds ... in pharmacology, brings a record of significant accomplishments ... in psychiatry.  Dr. Salinas has played ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Inc. (Nasdaq: AMLN ) today released the ... Wilson, providing shareholders with an update on recent developments:Dear ... am writing you today to provide a summary of ... details on the slate of highly qualified and experienced ...
... ThermoGenesis Corp. (Nasdaq: KOOL ), a ... and store adult stem cells, said today that its ... to be presented at the International Stem Cell Therapy ... abstracts will cover the efficacy of the Company,s BioArchive(R) ...
... CHARLOTTESVILLE, Virginia, April 2 Biovista Inc. today,announced ... has shown,significant positive results in the MOG-induced Experimental ... existing drug that,Biovista repositioned in MS and is ... in reducing symptoms and no toxic effects in ...
Cached Biology Technology:Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 2Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 3Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 4Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 5Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 6Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 7Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments 8ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference 2ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference 3ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference 4Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... from two universities in Italy and Virginia Tech in ... protein that is responsible for the production xanthurenic acid ... plays a key role in the sexual reproduction of ... Interfering with the formation of XA could be an ...
... Results from a new, five-year study show that regular use ... breast cancer by up to 71 percent and may offer ... cancers. , The study findings were released today at ... in Washington, D.C. , "We believe this is the ...
... you ever tried to do the limbo? For ants it's ... have discovered that ants are able to learn how to ... can successfully crawl under it without slowing down. Tobias Seidl ... Meeting for the Society for Experimental Biology on Tuesday 4th ...
Cached Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... is for when you need to make your ... transformation efficiency. Our services for preparing competent cells ... MCLab's custom competent cell service offers: ... Fast turnaround Quality control performance ...
... for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, ... * ... ... ...
Biology Products: